{Reference Type}: Case Reports
{Title}: A case of an advanced renal collecting duct carcinoma in which initial therapeutic effect was achieved with pembrolizumab plus axitinib.
{Author}: Atagi Y;Daizumoto K;Mohri S;Somiya K;Seto D;Nakanishi S;Yanagihara Y;Ninomiya I;Okamoto K;Yamashi S;
{Journal}: IJU Case Rep
{Volume}: 7
{Issue}: 1
{Year}: 2024 Jan
暂无{DOI}: 10.1002/iju5.12666
{Abstract}: <B>UNASSIGNED: </B>Renal collecting duct carcinoma is often found in advanced cancers and has a poor prognosis. Here, we present the case of symptomatic metastatic collecting duct carcinoma in which we observed an initial therapeutic effect of immune checkpoint inhibitors plus tyrosine kinase inhibitors.<BR><B>UNASSIGNED: </B>The patient was a 69-year-old male who was referred to our hospital for examination of a right chest tumor and related pain. Contrast-enhanced computed tomography and tumor biopsy were performed, leading to a diagnosis of collecting duct carcinoma. A combination of pembrolizumab plus axitinib was initiated as first-line therapy; right chest pain decreased, and tumor shrinkage was observed. Seven months after treatment initiation, tumor progression was noted. Cabozantinib was initiated as second-line therapy; however, was discontinued due to patient fatigue. The patient died 15 months after the initiation of treatment.<BR><B>UNASSIGNED: </B>For symptomatic metastatic collecting duct carcinoma, pembrolizumab plus axitinib may have initial therapeutic effects.